Aytu Q4 record revenue $30.7M, positive Adj. EBITDA $7.7M, prescriptions up 32%

AYTU BIOPHARMA, INC

Q4 net revenue $30.7M (+12% YoY); Rx segment $23.3M (+24%); total prescriptions 155,562 (+32%).
Net loss improved to $2.5M ($0.59/share) from $16.1M ($8.95/share) a year ago; $0.6M net income excluding impairment.
Adjusted EBITDA positive $7.7M in Q4 vs negative $3.9M; FY23 Adj. EBITDA positive $3.2M vs negative $21.5M.
Cash ended at $23.0M, up from $19.2M in March; company plans to monetize or discontinue Consumer Health segment.
Gross margin improved to 60% (Q4) and 62% (FY) from 54% in both prior-year periods.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

AYTU BIOPHARMA, INC reported the fiscal quarter ended June 30, 2023 results: revenue $30.7 million, net income $2.5 million, EPS $0.59 per share.

Period: the fiscal quarter ended June 30, 2023
Revenue: $30.7 million
Net income: $2.5 million
EPS: $0.59 per share
Result: reported results

Exact text from the filing

BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023 Q4 2023 net revenue of $30.7 million; Adjusted EBITDA of $7.7 million Record Q4 2023 total prescriptions increased 32% compared to Q4 2022 Rx Segment net revenue of $23.3 million and Adjusted EBITDA of $8.3 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

AYTU BIOPHARMA, INC reported the fiscal year ended June 30, 2023 results: revenue $107.4 million, net income $17.1 million, EPS $5.11 per share.

Period: the fiscal year ended June 30, 2023
Revenue: $107.4 million
Net income: $17.1 million
EPS: $5.11 per share
Result: reported results

Exact text from the filing

were $23.0 million at June 30, 2023 compared to $19.2 million at March 31, 2023. FY 2023 Commercial Highlights (12 months ending June 30, 2023) ● Total net revenue was $107.4 million, an increase of 11% from $96.7 million in net revenue in FY 2022. ● Net revenue from the Company’s Rx segment was $73.8 million during FY 2023 compared to $61.1 million in FY

View on SEC.gov

Browse all earnings releases →

AYTU BIOPHARMA, INC filing history →

Source: SEC EDGAR

accession 0001558370-23-016076

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.